Zobrazeno 1 - 10
of 824
pro vyhledávání: '"TROUGH LEVELS"'
Publikováno v:
Future Journal of Pharmaceutical Sciences, Vol 10, Iss 1, Pp 1-15 (2024)
Abstract Background Many clinical variables might impact the pharmacokinetics of calcineurin inhibitors (CIs). Different alleles of cytochromes P450 (CYP)3A4/5 and drug transporter P-glycoprotein are the main variables. Other variables include reloca
Externí odkaz:
https://doaj.org/article/06cde680358d425e9927969eaeb0a782
Autor:
Subhash Chander, Roopa Kumari, Hong Yu Wang, Yaqub Nadeem Mohammed, Om Parkash, Sindhu Lohana, FNU Sorath, Abhi Chand Lohana, FNU Sadarat, Sheena Shiwlani
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-16 (2024)
Abstract Background & objective The Infectious Disease Society of America guidelines recommend vancomycin trough levels of 15–20 mg/L for severe methicillin-resistant Staphylococcus aureus. However, recent consensus guidelines of four infectious di
Externí odkaz:
https://doaj.org/article/463fe5e627f54e8bac22fd285bb2441c
Autor:
Julian Felipe Ramirez-Osorio, Juan Esteban Velez-Hernandez, Nathalia Fernandez-Castaño, David Felipe Rojas-Hernandez, Fabian Jaimes
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background CKD patients on hemodialysis (HD) with Staphylococcus aureus (SA) bacteremia present high morbidity, mortality and increased risk of MRSA. Vancomycin is the antibiotic of choice in these cases, it has a narrow therapeutic margin a
Externí odkaz:
https://doaj.org/article/439f6d446d2c4a4e887070145ce33e7b
Autor:
Kristina Schönfelder, Birte Möhlendick, Ute Eisenberger, Andreas Kribben, Winfried Siffert, Falko M. Heinemann, Anja Gäckler, Benjamin Wilde, Justa Friebus-Kardash
Publikováno v:
Diagnostics, Vol 14, Iss 19, p 2202 (2024)
Background/Objectives: Our previous retrospective single-center cohort study found, at 3-year follow-up, a trend toward low tacrolimus trough levels and an increased risk of de novo donor-specific anti-HLA antibodies (DSAs) and of antibody-mediated r
Externí odkaz:
https://doaj.org/article/d93c3686f4fa4a33a24cacdf6a79f72e
Autor:
Jo L. Dehoorne, Helena Groth, Emma Carlé, Ilse De Schrijver, Celine Sys, Patricia Delbeke, Elke O. Kreps, Thomas Renson, Carolien Bonroy
Publikováno v:
Pediatric Rheumatology Online Journal, Vol 21, Iss 1, Pp 1-11 (2023)
Abstract Background Adalimumab is currently considered the most efficacious anti-TNFα agent for childhood noninfectious uveitis (NIU). The objective of this study was to define a therapeutic range for adalimumab trough levels in the treatment of chi
Externí odkaz:
https://doaj.org/article/a36938333bc7459b99d2d5631678c5ed
Publikováno v:
Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-9 (2023)
Abstract Background TNF-α inhibitor (TNFi) serum trough levels have previously been found to be related to disease activity in axial spondyloarthritis (axSpA). However, most research regarding serum trough levels has been conducted in patients who o
Externí odkaz:
https://doaj.org/article/a27c28729cba422a91c4cdc39990477a
Autor:
Alexander Born, Federica Bocchi, Christian Kuhn, Ursula Amstutz, Markus R. Baumgartner, Daniel Sidler
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
BackgroundCalcineurin inhibitors, including tacrolimus, remain a cornerstone of immunosuppressive therapy after kidney transplantation. However, the therapeutic window is narrow, and nephrotoxic side effects occur with overdose, while the risk of all
Externí odkaz:
https://doaj.org/article/eee74dc453574e5f9c0f3e80abd6cafe
Autor:
Margaux Lelong, Régis Josien, Marianne Coste-Burel, Marie Rimbert, Céline Bressollette-Bodin, Stéphane Nancey, Guillaume Bouguen, Matthieu Allez, Mélanie Serrero, Ludovic Caillo, Cléa Rouillon, Pierre Blanc, David Laharie, Raphaël Olivier, Laurent Peyrin-Biroulet, Nina Dib, Astrid De Maissin, Céline Montuclard, Caroline Trang-Poisson, Fabienne Vavasseur, Géraldine Gallot, Mathilde Berthome, Cécile Braudeau, Justine Chevreuil, Arnaud Bourreille, Catherine Le Berre
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundPatients with inflammatory bowel disease (IBD) may have a modified immune response to SARS-CoV-2. The objectives were to evaluate the prevalence of COVID-19 in patients treated with infliximab or vedolizumab, to analyze the factors associat
Externí odkaz:
https://doaj.org/article/bb5aa4f5ef734067852b695ae42f61b4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.